$AKRO Insider Trading
FREE EMAIL WATCHDOG
Get free email notifications about insider trading in Akero Therapeutics, Inc..
- Your email is safe with us.
- The service is free and you can unsubscribe at any time.
General | Insiders | Insider Transactions | Monthly Overview | Weekly Overview
Overview of all insider trading transactions in Akero Therapeutics, Inc.. Get notifications about new insider transactions in Akero Therapeutics, Inc. for free.
| Date | Ticker | Company | Owner | Relationship | Transaction | Code | Cost ($) | Shares | Transaction Value ($) | Total Shares | % Holdings |
|---|---|---|---|---|---|---|---|---|---|---|---|
| May 04 2021 | AKRO | Akero Therapeutics ... | Young Jonathan | Chief Operating Off ... | Sell | S | 30.56 | 3,055 | 93,361 | 167,065 | 170.1 K to 167.1 K (-1.80 %) |
| May 04 2021 | AKRO | Akero Therapeutics ... | White William Richard | Chief Financial Off ... | Option Exercise | M | 7.01 | 4,200 | 29,438 | 359,829 | |
| May 04 2021 | AKRO | Akero Therapeutics ... | White William Richard | Chief Financial Off ... | Sell | S | 30.56 | 4,200 | 128,352 | 2,270 | 6.5 K to 2.3 K (-64.91 %) |
| May 04 2021 | AKRO | Akero Therapeutics ... | White William Richard | Chief Financial Off ... | Buy | M | 7.01 | 4,200 | 29,438 | 6,470 | 2.3 K to 6.5 K (+185.02 %) |
| Apr 26 2021 | AKRO | Akero Therapeutics ... | Xu Yuan | Director | Option Exercise | A | 28.79 | 26,000 | 748,540 | 26,000 | |
| Feb 02 2021 | AKRO | Akero Therapeutics ... | Young Jonathan | Chief Operating Off ... | Sell | S | 29.92 | 200 | 5,984 | 176,230 | 176.4 K to 176.2 K (-0.11 %) |
| Feb 02 2021 | AKRO | Akero Therapeutics ... | Young Jonathan | Chief Operating Off ... | Sell | S | 29.19 | 2,855 | 83,337 | 176,430 | 179.3 K to 176.4 K (-1.59 %) |
| Jan 11 2021 | AKRO | Akero Therapeutics ... | Cheng Andrew | President & CEO | Option Exercise | M | 0.62 | 20,000 | 12,300 | 258,712 | |
| Jan 11 2021 | AKRO | Akero Therapeutics ... | Cheng Andrew | President & CEO | Gift | G | 0.00 | 3,000 | 0 | 359,989 | 363 K to 360 K (-0.83 %) |
| Jan 11 2021 | AKRO | Akero Therapeutics ... | Cheng Andrew | President & CEO | Buy | M | 0.62 | 20,000 | 12,300 | 362,989 | 343 K to 363 K (+5.83 %) |
| Jan 11 2021 | AKRO | Akero Therapeutics ... | Young Jonathan | Chief Operating Off ... | Option Exercise | M | 0.62 | 7,500 | 4,613 | 35,296 | |
| Jan 11 2021 | AKRO | Akero Therapeutics ... | Young Jonathan | Chief Operating Off ... | Sell | S | 28.12 | 10,000 | 281,200 | 179,285 | 189.3 K to 179.3 K (-5.28 %) |
| Jan 11 2021 | AKRO | Akero Therapeutics ... | Young Jonathan | Chief Operating Off ... | Buy | M | 0.62 | 7,500 | 4,613 | 189,285 | 181.8 K to 189.3 K (+4.13 %) |
| Dec 29 2020 | AKRO | Akero Therapeutics ... | Cheng Andrew | President & CEO | Option Exercise | M | 0.62 | 7,480 | 4,638 | 278,712 | |
| Dec 29 2020 | AKRO | Akero Therapeutics ... | Cheng Andrew | President & CEO | Option Exercise | M | 0.62 | 7,480 | 4,638 | 278,712 | |
| Dec 29 2020 | AKRO | Akero Therapeutics ... | Cheng Andrew | President & CEO | Buy | M | 0.62 | 7,480 | 4,638 | 342,989 | 335.5 K to 343 K (+2.23 %) |
| Dec 29 2020 | AKRO | Akero Therapeutics ... | Cheng Andrew | President & CEO | Buy | M | 0.62 | 7,480 | 4,638 | 342,989 | 335.5 K to 343 K (+2.23 %) |
| Oct 14 2020 | AKRO | Akero Therapeutics ... | Bitterman Kevin | Director | Sell | S | 28.93 | 13,000 | 376,090 | 11,780 | 24.8 K to 11.8 K (-52.46 %) |
| Jul 14 2020 | AKRO | Akero Therapeutics ... | Apple Tree Partners IV, L.P. | 10% Owner | Buy | P | 36.00 | 415,000 | 14,940,000 | 5,830,203 | 5.4 M to 5.8 M (+7.66 %) |
| Jul 14 2020 | AKRO | Akero Therapeutics ... | Apple Tree Partners IV, L.P. | 10% Owner | Buy | P | 36.00 | 415,000 | 14,940,000 | 5,830,203 | 5.4 M to 5.8 M (+7.66 %) |
| Jul 14 2020 | AKRO | Akero Therapeutics ... | Harrison Seth Loring | Director | Buy | P | 36.00 | 415,000 | 14,940,000 | 5,830,203 | 5.4 M to 5.8 M (+7.66 %) |
| Jul 14 2020 | AKRO | Akero Therapeutics ... | Harrison Seth Loring | Director | Buy | P | 36.00 | 415,000 | 14,940,000 | 5,830,203 | 5.4 M to 5.8 M (+7.66 %) |
| Jul 06 2020 | AKRO | Akero Therapeutics ... | venBio Global Strategic Fund I ... | Sell | S | 33.83 | 4,603 | 155,721 | 3,033,552 | 3 M to 3 M (-0.15 %) | |
| Jul 06 2020 | AKRO | Akero Therapeutics ... | venBio Global Strategic Fund I ... | Sell | S | 33.63 | 3,800 | 127,805 | 3,038,155 | 3 M to 3 M (-0.12 %) | |
| Jul 06 2020 | AKRO | Akero Therapeutics ... | venBio Global Strategic Fund I ... | Sell | S | 34.45 | 108,064 | 3,723,010 | 3,041,955 | 3.2 M to 3 M (-3.43 %) | |
| Jun 11 2020 | AKRO | Akero Therapeutics ... | Heyman Tomas J. | Director | Option Exercise | A | 25.04 | 26,000 | 651,040 | 26,000 | |
| Jun 02 2020 | AKRO | Akero Therapeutics ... | Henderson Jane | Director | Option Exercise | A | 25.20 | 13,000 | 327,600 | 13,000 | |
| Jun 02 2020 | AKRO | Akero Therapeutics ... | Iwicki Mark T | Director | Option Exercise | A | 25.20 | 13,000 | 327,600 | 13,000 | |
| Jun 02 2020 | AKRO | Akero Therapeutics ... | Bitterman Kevin | Director | Option Exercise | A | 25.20 | 13,000 | 327,600 | 13,000 | |
| Jun 02 2020 | AKRO | Akero Therapeutics ... | Graham G. Walmsley | Director | Option Exercise | A | 25.20 | 13,000 | 327,600 | 13,000 | |
| Jun 02 2020 | AKRO | Akero Therapeutics ... | Harrison Seth Loring | Director | Option Exercise | A | 25.20 | 13,000 | 327,600 | 13,000 | |
| Apr 01 2020 | AKRO | Akero Therapeutics ... | Graham G. Walmsley | Director | Option Exercise | M | 19.97 | 2,168 | 43,295 | 23,832 | |
| Apr 01 2020 | AKRO | Akero Therapeutics ... | Graham G. Walmsley | Director | Buy | M | 19.97 | 2,168 | 43,295 | 2,168 | 0 to 2.2 K |
| Mar 16 2020 | AKRO | Akero Therapeutics ... | Young Jonathan | Chief Operating Off ... | Option Exercise | M | 0.62 | 6,082 | 3,740 | 94,268 | |
| Mar 16 2020 | AKRO | Akero Therapeutics ... | Young Jonathan | Chief Operating Off ... | Option Exercise | M | 0.62 | 5,035 | 3,097 | 42,796 | |
| Mar 16 2020 | AKRO | Akero Therapeutics ... | Young Jonathan | Chief Operating Off ... | Buy | M | 0.62 | 6,082 | 3,740 | 183,600 | 177.5 K to 183.6 K (+3.43 %) |
| Mar 16 2020 | AKRO | Akero Therapeutics ... | Young Jonathan | Chief Operating Off ... | Buy | M | 0.62 | 5,035 | 3,097 | 177,518 | 172.5 K to 177.5 K (+2.92 %) |
| Mar 16 2020 | AKRO | Akero Therapeutics ... | Young Jonathan | Chief Operating Off ... | Option Exercise | M | 0.62 | 6,082 | 3,740 | 94,268 | |
| Mar 16 2020 | AKRO | Akero Therapeutics ... | Young Jonathan | Chief Operating Off ... | Option Exercise | M | 0.62 | 5,035 | 3,097 | 42,796 | |
| Mar 16 2020 | AKRO | Akero Therapeutics ... | Young Jonathan | Chief Operating Off ... | Buy | M | 0.62 | 6,082 | 3,740 | 183,600 | 177.5 K to 183.6 K (+3.43 %) |
| Mar 16 2020 | AKRO | Akero Therapeutics ... | Young Jonathan | Chief Operating Off ... | Buy | M | 0.62 | 5,035 | 3,097 | 177,518 | 172.5 K to 177.5 K (+2.92 %) |
| Mar 13 2020 | AKRO | Akero Therapeutics ... | Rolph Timothy | Chief Scientific Of ... | Option Exercise | M | 0.61 | 22,656 | 13,820 | 42,796 | |
| Mar 13 2020 | AKRO | Akero Therapeutics ... | Rolph Timothy | Chief Scientific Of ... | Option Exercise | M | 0.61 | 27,368 | 16,694 | 94,268 | |
| Mar 13 2020 | AKRO | Akero Therapeutics ... | Rolph Timothy | Chief Scientific Of ... | Buy | M | 0.61 | 22,656 | 13,820 | 242,933 | 220.3 K to 242.9 K (+10.29 %) |
| Mar 13 2020 | AKRO | Akero Therapeutics ... | Rolph Timothy | Chief Scientific Of ... | Buy | M | 0.61 | 27,368 | 16,694 | 220,277 | 192.9 K to 220.3 K (+14.19 %) |
| Mar 06 2020 | AKRO | Akero Therapeutics ... | venBio Global Strategic Fund I ... | 10% Owner | Sell | S | 23.79 | 1,800 | 42,831 | 3,150,019 | 3.2 M to 3.2 M (-0.06 %) |
| Mar 06 2020 | AKRO | Akero Therapeutics ... | venBio Global Strategic Fund I ... | 10% Owner | Sell | S | 23.53 | 8,500 | 200,011 | 3,151,819 | 3.2 M to 3.2 M (-0.27 %) |
| Mar 06 2020 | AKRO | Akero Therapeutics ... | venBio Global Strategic Fund I ... | 10% Owner | Sell | S | 23.81 | 35,650 | 848,766 | 3,160,319 | 3.2 M to 3.2 M (-1.12 %) |
| Mar 03 2020 | AKRO | Akero Therapeutics ... | venBio Global Strategic Fund I ... | 10% Owner | Sell | S | 23.00 | 6,401 | 147,199 | 3,195,969 | 3.2 M to 3.2 M (-0.20 %) |
| Mar 03 2020 | AKRO | Akero Therapeutics ... | venBio Global Strategic Fund I ... | 10% Owner | Sell | S | 23.06 | 10,297 | 237,459 | 3,202,370 | 3.2 M to 3.2 M (-0.32 %) |
| Mar 03 2020 | AKRO | Akero Therapeutics ... | venBio Global Strategic Fund I ... | 10% Owner | Sell | S | 21.30 | 5,100 | 108,652 | 3,212,667 | 3.2 M to 3.2 M (-0.16 %) |
| Feb 27 2020 | AKRO | Akero Therapeutics ... | venBio Global Strategic Fund I ... | 10% Owner | Sell | S | 22.54 | 1,781 | 40,144 | 3,227,767 | 3.2 M to 3.2 M (-0.06 %) |
| Feb 27 2020 | AKRO | Akero Therapeutics ... | venBio Global Strategic Fund I ... | 10% Owner | Sell | S | 22.44 | 2,523 | 56,615 | 3,229,548 | 3.2 M to 3.2 M (-0.08 %) |
| Feb 27 2020 | AKRO | Akero Therapeutics ... | venBio Global Strategic Fund I ... | 10% Owner | Sell | S | 23.67 | 1,600 | 37,876 | 3,232,071 | 3.2 M to 3.2 M (-0.05 %) |
| Feb 12 2020 | AKRO | Akero Therapeutics ... | venBio Global Strategic Fund I ... | 10% Owner | Sell | S | 27.14 | 6 | 163 | 3,233,671 | 3.2 M to 3.2 M (0.00 %) |
| Feb 12 2020 | AKRO | Akero Therapeutics ... | venBio Global Strategic Fund I ... | 10% Owner | Sell | S | 27.05 | 2,184 | 59,068 | 3,233,677 | 3.2 M to 3.2 M (-0.07 %) |
| Feb 12 2020 | AKRO | Akero Therapeutics ... | venBio Global Strategic Fund I ... | 10% Owner | Sell | S | 27.08 | 7,836 | 212,168 | 3,225,861 | 3.2 M to 3.2 M (-0.24 %) |
| Feb 10 2020 | AKRO | Akero Therapeutics ... | Atlas Venture Opportunity Fund ... | 10% Owner | Sell | J | 0.00 | 50,510 | 0 | 404,079 | 454.6 K to 404.1 K (-11.11 %) |
| Feb 10 2020 | AKRO | Akero Therapeutics ... | venBio Global Strategic Fund I ... | 10% Owner | Sell | S | 27.03 | 6,102 | 164,955 | 3,233,697 | 3.2 M to 3.2 M (-0.19 %) |
| Feb 06 2020 | AKRO | Akero Therapeutics ... | venBio Global Strategic Fund I ... | 10% Owner | Sell | S | 25.99 | 28,608 | 743,548 | 3,239,799 | 3.3 M to 3.2 M (-0.88 %) |
| Feb 06 2020 | AKRO | Akero Therapeutics ... | venBio Global Strategic Fund I ... | 10% Owner | Sell | S | 25.65 | 53,731 | 1,378,179 | 3,268,407 | 3.3 M to 3.3 M (-1.62 %) |
| Jan 21 2020 | AKRO | Akero Therapeutics ... | Versant Venture Capital VI, L. ... | 10% Owner | Sell | S | 22.39 | 17,849 | 399,639 | 3,092,698 | 3.1 M to 3.1 M (-0.57 %) |
| Jan 21 2020 | AKRO | Akero Therapeutics ... | Versant Venture Capital VI, L. ... | 10% Owner | Sell | S | 21.78 | 8,091 | 176,222 | 3,110,547 | 3.1 M to 3.1 M (-0.26 %) |
| Jan 21 2020 | AKRO | Akero Therapeutics ... | Versant Venture Capital VI, L. ... | 10% Owner | Sell | S | 20.09 | 11,103 | 223,059 | 3,118,638 | 3.1 M to 3.1 M (-0.35 %) |
| Jan 21 2020 | AKRO | Akero Therapeutics ... | Versant Venture Capital VI, L. ... | 10% Owner | Sell | S | 19.72 | 22,489 | 443,483 | 3,129,741 | 3.2 M to 3.1 M (-0.71 %) |
| Jan 15 2020 | AKRO | Akero Therapeutics ... | Versant Venture Capital VI, L. ... | 10% Owner | Sell | S | 19.73 | 7,511 | 148,192 | 3,152,230 | 3.2 M to 3.2 M (-0.24 %) |
| Jan 15 2020 | AKRO | Akero Therapeutics ... | Versant Venture Capital VI, L. ... | 10% Owner | Sell | S | 19.73 | 7,511 | 148,192 | 3,152,230 | 3.2 M to 3.2 M (-0.24 %) |
| Jan 15 2020 | AKRO | Akero Therapeutics ... | Versant Venture Capital VI, L. ... | 10% Owner | Sell | S | 20.00 | 12,307 | 246,140 | 3,159,741 | 3.2 M to 3.2 M (-0.39 %) |
| Jan 15 2020 | AKRO | Akero Therapeutics ... | Versant Venture Capital VI, L. ... | 10% Owner | Sell | S | 20.00 | 12,307 | 246,140 | 3,159,741 | 3.2 M to 3.2 M (-0.39 %) |
| Jan 15 2020 | AKRO | Akero Therapeutics ... | Versant Venture Capital VI, L. ... | 10% Owner | Sell | S | 20.84 | 83 | 1,730 | 3,172,048 | 3.2 M to 3.2 M (0.00 %) |
| Jan 15 2020 | AKRO | Akero Therapeutics ... | Versant Venture Capital VI, L. ... | 10% Owner | Sell | S | 20.84 | 83 | 1,730 | 3,172,048 | 3.2 M to 3.2 M (0.00 %) |
| Jan 15 2020 | AKRO | Akero Therapeutics ... | Versant Venture Capital VI, L. ... | 10% Owner | Sell | S | 20.16 | 11,593 | 233,715 | 3,172,131 | 3.2 M to 3.2 M (-0.36 %) |
| Jan 15 2020 | AKRO | Akero Therapeutics ... | Versant Venture Capital VI, L. ... | 10% Owner | Sell | S | 20.16 | 11,593 | 233,715 | 3,172,131 | 3.2 M to 3.2 M (-0.36 %) |
| Jan 15 2020 | AKRO | Akero Therapeutics ... | Versant Venture Capital VI, L. ... | 10% Owner | Sell | S | 20.10 | 19,343 | 388,794 | 3,183,724 | 3.2 M to 3.2 M (-0.60 %) |
| Jan 15 2020 | AKRO | Akero Therapeutics ... | Versant Venture Capital VI, L. ... | 10% Owner | Sell | S | 20.10 | 19,343 | 388,794 | 3,183,724 | 3.2 M to 3.2 M (-0.60 %) |
| Jan 14 2020 | AKRO | Akero Therapeutics ... | venBio Global Strategic Fund I ... | 10% Owner | Sell | S | 20.23 | 494,000 | 9,993,620 | 3,322,138 | 3.8 M to 3.3 M (-12.95 %) |
| Jan 10 2020 | AKRO | Akero Therapeutics ... | Young Jonathan | Chief Operating Off ... | Option Exercise | M | 0.62 | 21,286 | 13,091 | 100,350 | |
| Jan 10 2020 | AKRO | Akero Therapeutics ... | Young Jonathan | Chief Operating Off ... | Option Exercise | M | 0.62 | 17,621 | 10,837 | 47,831 | |
| Jan 10 2020 | AKRO | Akero Therapeutics ... | Young Jonathan | Chief Operating Off ... | Buy | M | 0.62 | 21,286 | 13,091 | 232,483 | 211.2 K to 232.5 K (+10.08 %) |
| Jan 10 2020 | AKRO | Akero Therapeutics ... | Young Jonathan | Chief Operating Off ... | Buy | M | 0.62 | 17,621 | 10,837 | 211,197 | 193.6 K to 211.2 K (+9.10 %) |
| Jan 10 2020 | AKRO | Akero Therapeutics ... | Young Jonathan | Chief Operating Off ... | Option Exercise | M | 0.62 | 21,286 | 13,091 | 100,350 | |
| Jan 10 2020 | AKRO | Akero Therapeutics ... | Young Jonathan | Chief Operating Off ... | Option Exercise | M | 0.62 | 17,621 | 10,837 | 47,831 | |
| Jan 10 2020 | AKRO | Akero Therapeutics ... | Young Jonathan | Chief Operating Off ... | Buy | M | 0.62 | 21,286 | 13,091 | 232,483 | 211.2 K to 232.5 K (+10.08 %) |
| Jan 10 2020 | AKRO | Akero Therapeutics ... | Young Jonathan | Chief Operating Off ... | Buy | M | 0.62 | 17,621 | 10,837 | 211,197 | 193.6 K to 211.2 K (+9.10 %) |
| Jan 10 2020 | AKRO | Akero Therapeutics ... | venBio Global Strategic Fund I ... | 10% Owner | Sell | S | 19.86 | 15,677 | 311,355 | 3,816,138 | 3.8 M to 3.8 M (-0.41 %) |
| Jan 09 2020 | AKRO | Akero Therapeutics ... | Versant Venture Capital VI, L. ... | 10% Owner | Sell | S | 20.21 | 16,527 | 334,011 | 3,203,067 | 3.2 M to 3.2 M (-0.51 %) |
| Jan 09 2020 | AKRO | Akero Therapeutics ... | Versant Venture Capital VI, L. ... | 10% Owner | Sell | S | 19.80 | 22,368 | 442,886 | 3,219,594 | 3.2 M to 3.2 M (-0.69 %) |
| Jan 09 2020 | AKRO | Akero Therapeutics ... | Versant Venture Capital VI, L. ... | 10% Owner | Sell | S | 20.05 | 14,162 | 283,948 | 3,241,962 | 3.3 M to 3.2 M (-0.43 %) |
| Jan 08 2020 | AKRO | Akero Therapeutics ... | venBio Global Strategic Fund I ... | 10% Owner | Sell | S | 20.17 | 31,000 | 625,149 | 3,831,815 | 3.9 M to 3.8 M (-0.80 %) |
| Jan 08 2020 | AKRO | Akero Therapeutics ... | venBio Global Strategic Fund I ... | 10% Owner | Sell | S | 19.64 | 42,221 | 829,381 | 3,862,815 | 3.9 M to 3.9 M (-1.08 %) |
| Jan 06 2020 | AKRO | Akero Therapeutics ... | Versant Venture Capital VI, L. ... | 10% Owner | Sell | S | 19.93 | 42,323 | 843,497 | 3,256,124 | 3.3 M to 3.3 M (-1.28 %) |
| Jan 06 2020 | AKRO | Akero Therapeutics ... | Versant Venture Capital VI, L. ... | 10% Owner | Sell | S | 18.32 | 6,101 | 111,770 | 3,298,447 | 3.3 M to 3.3 M (-0.18 %) |
| Jan 06 2020 | AKRO | Akero Therapeutics ... | Versant Venture Capital VI, L. ... | 10% Owner | Sell | S | 17.68 | 4,968 | 87,834 | 3,304,548 | 3.3 M to 3.3 M (-0.15 %) |
| Jan 06 2020 | AKRO | Akero Therapeutics ... | Versant Venture Capital VI, L. ... | 10% Owner | Sell | S | 20.27 | 100 | 2,027 | 3,309,516 | 3.3 M to 3.3 M (0.00 %) |
| Jan 06 2020 | AKRO | Akero Therapeutics ... | Versant Venture Capital VI, L. ... | 10% Owner | Sell | S | 19.18 | 3,100 | 59,458 | 3,309,616 | 3.3 M to 3.3 M (-0.09 %) |
| Jan 06 2020 | AKRO | Akero Therapeutics ... | Versant Venture Capital VI, L. ... | 10% Owner | Sell | J | 0.00 | 11,803 | 0 | 0 | 11.8 K to 0 (-100.00 %) |
| Jan 06 2020 | AKRO | Akero Therapeutics ... | Versant Venture Capital VI, L. ... | 10% Owner | Buy | J | 0.00 | 11,803 | 0 | 11,803 | 0 to 11.8 K |
| Jan 06 2020 | AKRO | Akero Therapeutics ... | Versant Venture Capital VI, L. ... | 10% Owner | Sell | J | 0.00 | 13,683 | 0 | 0 | 13.7 K to 0 (-100.00 %) |
| Jan 06 2020 | AKRO | Akero Therapeutics ... | Versant Venture Capital VI, L. ... | 10% Owner | Buy | J | 0.00 | 13,683 | 0 | 13,683 | 0 to 13.7 K |
| Jan 06 2020 | AKRO | Akero Therapeutics ... | Versant Venture Capital VI, L. ... | 10% Owner | Sell | J | 0.00 | 684,143 | 0 | 3,312,716 | 4 M to 3.3 M (-17.12 %) |
| Jan 06 2020 | AKRO | Akero Therapeutics ... | Versant Venture Capital VI, L. ... | 10% Owner | Sell | S | 22.17 | 1,000 | 22,170 | 3,996,859 | 4 M to 4 M (-0.03 %) |
| Jan 06 2020 | AKRO | Akero Therapeutics ... | Versant Venture Capital VI, L. ... | 10% Owner | Sell | S | 21.20 | 3,900 | 82,680 | 3,997,859 | 4 M to 4 M (-0.10 %) |
| Jan 06 2020 | AKRO | Akero Therapeutics ... | Versant Venture Capital VI, L. ... | 10% Owner | Sell | S | 19.89 | 10,952 | 217,835 | 4,001,759 | 4 M to 4 M (-0.27 %) |
| Jan 06 2020 | AKRO | Akero Therapeutics ... | venBio Global Strategic Fund I ... | 10% Owner | Sell | S | 19.30 | 12,498 | 241,214 | 3,905,036 | 3.9 M to 3.9 M (-0.32 %) |
| Jan 06 2020 | AKRO | Akero Therapeutics ... | venBio Global Strategic Fund I ... | 10% Owner | Sell | S | 19.94 | 23,000 | 458,507 | 3,917,534 | 3.9 M to 3.9 M (-0.58 %) |
| Jan 02 2020 | AKRO | Akero Therapeutics ... | Atlas Venture Fund XI, L.P. | 10% Owner | Sell | J | 0.00 | 242,883 | 0 | 2,706,412 | 2.9 M to 2.7 M (-8.24 %) |
| Dec 31 2019 | AKRO | Akero Therapeutics ... | Versant Venture Capital VI, L. ... | 10% Owner | Sell | S | 23.48 | 17,207 | 404,020 | 3,656,585 | 3.7 M to 3.7 M (-0.47 %) |
| Dec 31 2019 | AKRO | Akero Therapeutics ... | Versant Venture Capital VI, L. ... | 10% Owner | Sell | S | 24.39 | 338,919 | 8,266,234 | 3,673,792 | 4 M to 3.7 M (-8.45 %) |
| Dec 31 2019 | AKRO | Akero Therapeutics ... | Versant Venture Capital VI, L. ... | 10% Owner | Sell | S | 22.58 | 33,256 | 750,920 | 4,012,711 | 4 M to 4 M (-0.82 %) |
| Dec 31 2019 | AKRO | Akero Therapeutics ... | Young Jonathan | Chief Operating Off ... | Buy | W | 0.00 | 667 | 0 | 193,576 | 192.9 K to 193.6 K (+0.35 %) |
| Dec 26 2019 | AKRO | Akero Therapeutics ... | Versant Venture Capital VI, L. ... | 10% Owner | Sell | S | 22.48 | 23,600 | 530,528 | 4,045,967 | 4.1 M to 4 M (-0.58 %) |
| Dec 26 2019 | AKRO | Akero Therapeutics ... | Versant Venture Capital VI, L. ... | 10% Owner | Sell | S | 21.70 | 1,605 | 34,829 | 4,069,567 | 4.1 M to 4.1 M (-0.04 %) |
| Dec 26 2019 | AKRO | Akero Therapeutics ... | Versant Venture Capital VI, L. ... | 10% Owner | Sell | S | 21.56 | 5,433 | 117,135 | 4,071,172 | 4.1 M to 4.1 M (-0.13 %) |
| Dec 26 2019 | AKRO | Akero Therapeutics ... | Versant Venture Capital VI, L. ... | 10% Owner | Sell | S | 19.80 | 18,582 | 367,924 | 4,076,605 | 4.1 M to 4.1 M (-0.45 %) |
| Dec 19 2019 | AKRO | Akero Therapeutics ... | Versant Venture Capital VI, L. ... | 10% Owner | Sell | S | 19.50 | 2,020 | 39,390 | 4,095,187 | 4.1 M to 4.1 M (-0.05 %) |
| Dec 19 2019 | AKRO | Akero Therapeutics ... | Versant Venture Capital VI, L. ... | 10% Owner | Sell | S | 19.58 | 7,651 | 149,807 | 4,097,207 | 4.1 M to 4.1 M (-0.19 %) |
| Dec 19 2019 | AKRO | Akero Therapeutics ... | Versant Venture Capital VI, L. ... | 10% Owner | Sell | S | 19.50 | 2,020 | 39,390 | 4,095,187 | 4.1 M to 4.1 M (-0.05 %) |
| Dec 19 2019 | AKRO | Akero Therapeutics ... | Versant Venture Capital VI, L. ... | 10% Owner | Sell | S | 19.58 | 7,651 | 149,807 | 4,097,207 | 4.1 M to 4.1 M (-0.19 %) |
| Dec 19 2019 | AKRO | Akero Therapeutics ... | Atlas Venture Fund XI, L.P. | 10% Owner | Sell | J | 0.00 | 50,510 | 0 | 454,589 | 505.1 K to 454.6 K (-10.00 %) |
| Dec 19 2019 | AKRO | Akero Therapeutics ... | Atlas Venture Fund XI, L.P. | 10% Owner | Sell | J | 0.00 | 520,464 | 0 | 2,949,295 | 3.5 M to 2.9 M (-15.00 %) |
| Dec 13 2019 | AKRO | Akero Therapeutics ... | Cheng Andrew | Chief Executive Off ... | Option Exercise | A | 21.09 | 234,000 | 4,935,060 | 234,000 | |
| Dec 13 2019 | AKRO | Akero Therapeutics ... | Cheng Andrew | Chief Executive Off ... | Option Exercise | A | 21.09 | 234,000 | 4,935,060 | 234,000 | |
| Dec 13 2019 | AKRO | Akero Therapeutics ... | White William Richard | Chief Financial Off ... | Option Exercise | A | 21.09 | 85,000 | 1,792,650 | 85,000 | |
| Dec 13 2019 | AKRO | Akero Therapeutics ... | White William Richard | Chief Financial Off ... | Option Exercise | A | 21.09 | 85,000 | 1,792,650 | 85,000 | |
| Dec 13 2019 | AKRO | Akero Therapeutics ... | Young Jonathan | Chief Operating Off ... | Option Exercise | A | 21.09 | 85,000 | 1,792,650 | 85,000 | |
| Dec 13 2019 | AKRO | Akero Therapeutics ... | Young Jonathan | Chief Operating Off ... | Option Exercise | A | 21.09 | 85,000 | 1,792,650 | 85,000 | |
| Dec 13 2019 | AKRO | Akero Therapeutics ... | Yale Catriona | Chief Development O ... | Option Exercise | A | 21.09 | 85,000 | 1,792,650 | 85,000 | |
| Dec 13 2019 | AKRO | Akero Therapeutics ... | Yale Catriona | Chief Development O ... | Option Exercise | A | 21.09 | 85,000 | 1,792,650 | 85,000 | |
| Dec 13 2019 | AKRO | Akero Therapeutics ... | Rolph Timothy | Chief Scientific Of ... | Option Exercise | A | 21.09 | 85,000 | 1,792,650 | 85,000 | |
| Dec 13 2019 | AKRO | Akero Therapeutics ... | Rolph Timothy | Chief Scientific Of ... | Option Exercise | A | 21.09 | 85,000 | 1,792,650 | 85,000 | |
| Nov 12 2019 | AKRO | Akero Therapeutics ... | Harrison Seth Loring | Director | Option Exercise | A | 19.97 | 26,000 | 519,220 | 26,000 | |
| Nov 12 2019 | AKRO | Akero Therapeutics ... | Graham G. Walmsley | Director | Option Exercise | A | 19.97 | 26,000 | 519,220 | 26,000 | |
| Nov 12 2019 | AKRO | Akero Therapeutics ... | Bitterman Kevin | Director | Option Exercise | A | 19.97 | 26,000 | 519,220 | 26,000 | |
| Jun 25 2019 | AKRO | Akero Therapeutics ... | Bitterman Kevin | Director | Option Exercise | C | 0.00 | 722,737 | 0 | 0 | |
| Jun 25 2019 | AKRO | Akero Therapeutics ... | Bitterman Kevin | Director | Option Exercise | C | 0.00 | 10,666,667 | 0 | 0 | |
| Jun 25 2019 | AKRO | Akero Therapeutics ... | Bitterman Kevin | Director | Buy | P | 16.00 | 270,000 | 4,320,000 | 505,099 | 235.1 K to 505.1 K (+114.85 %) |
| Jun 25 2019 | AKRO | Akero Therapeutics ... | Bitterman Kevin | Director | Buy | C | 0.00 | 235,099 | 0 | 235,099 | 0 to 235.1 K |
| Jun 25 2019 | AKRO | Akero Therapeutics ... | Bitterman Kevin | Director | Buy | C | 0.00 | 3,469,759 | 0 | 3,469,759 | 0 to 3.5 M |
| Jun 25 2019 | AKRO | Akero Therapeutics ... | Atlas Venture Fund XI, L.P. | 10% Owner | Option Exercise | C | 0.00 | 722,737 | 0 | 0 | |
| Jun 25 2019 | AKRO | Akero Therapeutics ... | Atlas Venture Fund XI, L.P. | 10% Owner | Option Exercise | C | 0.00 | 10,666,667 | 0 | 0 | |
| Jun 25 2019 | AKRO | Akero Therapeutics ... | Atlas Venture Fund XI, L.P. | 10% Owner | Buy | P | 16.00 | 270,000 | 4,320,000 | 505,099 | 235.1 K to 505.1 K (+114.85 %) |
| Jun 25 2019 | AKRO | Akero Therapeutics ... | Atlas Venture Fund XI, L.P. | 10% Owner | Buy | C | 0.00 | 235,099 | 0 | 235,099 | 0 to 235.1 K |
| Jun 25 2019 | AKRO | Akero Therapeutics ... | Atlas Venture Fund XI, L.P. | 10% Owner | Buy | C | 0.00 | 3,469,759 | 0 | 3,469,759 | 0 to 3.5 M |
| Jun 25 2019 | AKRO | Akero Therapeutics ... | Royston Aaron | Director | Option Exercise | C | 0.00 | 722,737 | 0 | 0 | |
| Jun 25 2019 | AKRO | Akero Therapeutics ... | Royston Aaron | Director | Option Exercise | C | 0.00 | 10,666,667 | 0 | 0 | |
| Jun 25 2019 | AKRO | Akero Therapeutics ... | Royston Aaron | Director | Buy | C | 0.00 | 235,099 | 0 | 3,954,858 | 3.7 M to 4 M (+6.32 %) |
| Jun 25 2019 | AKRO | Akero Therapeutics ... | Royston Aaron | Director | Buy | C | 0.00 | 3,469,759 | 0 | 3,719,759 | 250 K to 3.7 M (+1,387.90 %) |
| Jun 25 2019 | AKRO | Akero Therapeutics ... | Royston Aaron | Director | Buy | P | 16.00 | 250,000 | 4,000,000 | 250,000 | 0 to 250 K |
| Jun 25 2019 | AKRO | Akero Therapeutics ... | Versant Venture Capital VI, L. ... | 10% Owner | Option Exercise | C | 0.00 | 722,737 | 0 | 0 | |
| Jun 25 2019 | AKRO | Akero Therapeutics ... | Versant Venture Capital VI, L. ... | 10% Owner | Option Exercise | C | 0.00 | 10,666,667 | 0 | 0 |